<DOC>
	<DOCNO>NCT01153100</DOCNO>
	<brief_summary>The investigator anticipate use Glargine decrease duration insulin drip , dose short-acting insulin drip , hospital ICU ( intensive care unit ) length stay , improve glycemic control , prevent rebound hyperglycemias insulin drip discontinue .</brief_summary>
	<brief_title>Effectiveness Adding Subcutaneous Long-acting Glargine Insulin Drip Therapy Compared With Standard Insulin Drip Therapy</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diabetic ketoacidosis ( DKA ) hyperglycemic hyperosmolar nonketotic state , hyperglycemia severe illness , pre postoperative state , nothing mouth ( NPO ) , well gastric ( tube feed ) parenteral nutrition require insulin drip . Patients type 1 type 2 diabetes mellitus ( DM ) include . Patients types diabetes among treated insulin drip NPO , severe concomitant illness receive enteral parenteral nutrition . Patients age 19 80 . Inability consent study reason include cognitive impairment secondary hyperglycemia , presence severe medical condition require intubation , severe sepsis , hypothermia , anticipated length insulin drip 2 week longer , pregnancy , Lantus allergy , concurrent sulfonamide treatment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Diabetes</keyword>
</DOC>